▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #299 by analyst upside · 2026-11-13
CDXS
Codexis, Inc.
Healthcare · Market Cap $105M · P/E 0x
ANALYST PRICE TARGET
+541.2%
implied upside to consensus target
Current Price $0.96
Consensus Target $6.14
Bull Target $11.0
Bear Target $2.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
2
Sell
0
52-Week Low $0.9
52-Week High $2.98
YTD Return -40.4%
FUNDAMENTALS
Market Cap $105M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.33
PEG Ratio 13.53
Dividend Yield N/A
Revenue (TTM) $78M
Profit Margin -39.6%
52-WEEK RANGE
52-Week Low $0.9
52-Week High $2.98
Current Price $0.96
Bear Target $2.0
Bull Target $11.0
● Now $0.96 ● Target $6.14
TRADING DATA
Avg Volume 905K
YTD Return -40.4%
Analyst Count 7
Consensus Buy
Upside to Target +541.2%
Last Updated 2026-11-13

ANALYST SUMMARY

Codexis, Inc. (CDXS) is currently trading at $0.96 with a Wall Street consensus price target of $6.14, implying potential upside of 541.2% over the next 12 months. 7 analysts currently cover CDXS, with a consensus rating of Buy - 71% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $2.0.

CDXS operates in the Healthcare sector with a market capitalisation of $105M. The stock is down 40.4% year-to-date and is currently trading near the lower end of its 52-week range of $0.9 – $2.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ZVRA +126.3%
Zevra Therapeutics, Inc.
$664M · P/E 9.1x · Buy
JYNT +34.5%
The Joint Corp.
$92M · P/E 30.4x · Hold
TCMD +35.5%
Tactile Systems Technology, Inc.
$601M · P/E 26.0x · Buy
OMCL +64.3%
Omnicell, Inc.
$2B · P/E 36.4x · Buy
ATRC +15.9%
AtriCure, Inc.
$3B · P/E 180.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CDXS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Overweight → Overweight 2026-08-17 14% win rate (7 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-11-22 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-11-15 40% win rate (10 calls)
Benchmark reit
Hold 2024-11-04 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-20 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-08-29 40% win rate (10 calls)
Benchmark ↓ Downgrade
Buy → Hold 2024-08-19 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-08-09 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
30
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →